Menu
Back to Journals » Journal of Experimental Pharmacology » Volume 12
Enhanced Efficacy of Chemically Modified Curcumin in Experimental Periodontitis: Systemic Implications [Corrigendum]
Wang HH, Lee HM, Raja V, et al. J Exp Pharmacol. 2019;11:1–14.
On page 13 the disclosure section should be presented as follows:
Disclosure
LMG is listed as an inventor on several related patents and these have been fully assigned to his institution, Stony Brook University, The State University of New York (SUNY). FJ is also listed as an inventor on several related patents which have been fully assigned to Stony Brook University and to Chem-Master Int. Inc. on a shared basis. In addition, both LMG and FJ are minor shareholders in Traverse BioSciences, Inc., and JS is president and major shareholder in Traverse. All other authors declare that there are no conflicts of interest regarding the publication of this paper.
Read the original article
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.